ReviewVirusdisease2020
SARS-CoV, MERS-CoV, and 2019-nCoV viruses: an overview of origin, evolution, and genetic variations.
Review in Virusdisease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 60 citations in OpenAlex.
- A narrative review of heterogeneity in SARS-CoV-2 infection outcomes and vaccine efficacy: strategizing pandemic preparedness in Africa.Frontiers in public health · 2026Review
- Thousands-years-old deep-sea DNA viruses reveal the evolution of human pathogenic viruses.Journal of advanced research · 2026Article
- Insights from integrated covalent docking and molecular dynamics simulations of nirmatrelvir analogs as potential SARS-CoV-2 MScientific reports · 2025Article
- Viral N protein hijacks deaminase-containing RNA granules to enhance SARS-CoV-2 mutagenesis.The EMBO journal · 2024Article
- Affinity Tag-Free Purification of SARS-CoV-2 N Protein and Its Crystal Structure in Complex with ssDNA.Biomolecules · 2024Article
- In Silico Identification of Potential Inhibitors of SARS-CoV-2 Main Protease (MPathogens (Basel, Switzerland) · 2024Article
- Sulfated Glycans Inhibit the Interaction of MERS-CoV Receptor Binding Domain with Heparin.Viruses · 2024Article
- SARS-CoV-2 and Brain Health: New Challenges in the Era of the Pandemic.Microorganisms · 2023Review
- The Cardiac Comeback-Beating Stronger: Exploring the Remarkable Resilience of the Heart in COVID-19 Recovery through Cardiac Autonomic Analysis.Medicina (Kaunas, Lithuania) · 2023Article
- In Silico Design of New Dual Inhibitors of SARS-CoV-2 MInternational journal of molecular sciences · 2023Article
- A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity.Molecules (Basel, Switzerland) · 2023Review
- Recent updates on liposomal formulations for detection, prevention and treatment of coronavirus disease (COVID-19).International journal of pharmaceutics · 2023Review
- SARS-CoV-2 accessory proteins involvement in inflammatory and profibrotic processes through IL11 signaling.Frontiers in immunology · 2023Article
- Review
- Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.Journal of medicinal chemistry · 2022Review
- Promising natural products against SARS-CoV-2: Structure, function, and clinical trials.Phytotherapy research : PTR · 2022Review
- Insights into COVID-19 vaccines development: Translation from benchside to bedside.Health sciences review (Oxford, England) · 2022Review
- Conserved protein targets for developing pan-coronavirus drugs based on sequence and 3D structure similarity analyses.Computers in biology and medicine · 2022Article
- Coronavirus infections from 2002 to 2021: neuropsychiatric manifestations.Sleep medicine · 2022Article
- Infection and Severity of COVID-19 Infection Among Healthcare Workers: A Report from Egypt.Infectious disorders drug targets · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronaviruses are single stranded RNA viruses usually present in bats (reservoir hosts), and are generally lethal, highly transmissible, and pathogenic viruses causing sever morbidity and mortality rates in human. Several animals including civets, camels, etc. have been identified as intermediate hosts enabling effective recombination of these viruses to emerge as new virulent and pathogenic strains. Among the seven known human coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV) have evolved as severe pathogenic forms infecting the human respiratory tract. About 8096 cases and 774 deaths were reported worldwide with the SARS-CoV infection during year 2002; 2229 cases and 791 deaths were reported for the MERS-CoV that emerged during 2012. Recently ~ 33,849,737 cases and 1,012,742 deaths (data as on 30 Sep 2020) were reported from the recent evolver SARS-CoV-2 infection. Studies on epidemiology and pathogenicity have shown that the viral spread was potentially caused by the contact route especially through the droplets, aerosols, and contaminated fomites. Genomic studies have confirmed the role of the viral spike protein in virulence and pathogenicity. They target the respiratory tract of the human causing severe progressive pneumonia affecting other organs like central nervous system in case of SARS-CoV, severe renal failure in MERS-CoV, and multi-organ failure in SARS-CoV-2. Herein, with respect to current awareness and role of coronaviruses in global public health, we review the various factors involving the origin, evolution, and transmission including the genetic variations observed, epidemiology, and pathogenicity of the three potential coronaviruses variants SARS-CoV, MERS-CoV, and 2019-nCoV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.